COMPARE II: biolimus eluting stent with biodegradable polymer versus everolimus at 3 years.

This study randomized 2:1 – 2707 patients to biolimus eluting stent with biodegradable polymer versus everolimus eluting stent with permanent polymer. At one year, the results were similar demonstrating the biolimus eluting stent noninferiority. At three years cardiac death, myocardial infarction and target vessel revascularization rates remained similar with 11% for biolimus eluting stent and 10.7% for the everolimus-eluting stent (p = 0.76).

Stent thrombosis was 1.2% for biolimus group and 0.8% for the everolimus group. In the subgroup analysis, the everolimus-eluting stent was superior in diabetic patients (p = 0.0378). 

Conclusion 

At 3-year follow up the biolimus eluting stent is equivalent to everolimus eluting stent. 

8_pieter_smits
Pieter Smits
2014-05-22

Title: The 3-year results from the COMPARE II trial

More articles by this author

IBERIAN: appendage occlusion registry

The aim of this study was to observe the rate of thromboembolic and hemorrhagic events in a period of 2 years in 167 patients...

Bivalirudin superior than heparin beyond the use or not of Glycoprotein inhibitors

Bivalirudin benefits in bleeding events versus heparin plus glycoprotein IIbIIIa inhibitors is clear even though  this benefit has not been fully studied at the...

Meta-analysis confirms the reduction in ischemic events with 2nd generation DES versus BMS

This paper included 5 studies that randomized patients to conventional stent versus chromium cobalt everolimus eluting stent; at 2 years, a significantly lower risk...

PARIS register: Non-adherence impact to antiplatelet therapy among men and women

The PARIS registry was a prospective observational study in 5018 patients undergoing coronary angioplasty with stent implantation in 15 centers. Three categories were prespecified...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...